As per MRFR analysis, the US Cardiac Biomarkers Market Size was estimated at 2.77 (USD Billion) in 2023. The US Cardiac Biomarkers Market Industry is expected to grow from 3.6(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Cardiac Biomarkers Market CAGR (growth rate) is expected to be around 11.981% during the forecast period (2025 - 2035).
The US Cardiac Biomarkers Market is currently witnessing significant trends driven largely by the rising prevalence of cardiovascular diseases across the nation. As reported by the CDC, heart disease remains a leading cause of death in the United States, pushing healthcare providers and institutions to invest in innovative diagnostic tools, including cardiac biomarkers. This increasing focus on early diagnosis and preventive care is a crucial market driver, promoting the development and adoption of advanced biomarker tests that enhance patient outcomes.
Opportunities in this market are plentiful, particularly as technology evolves. The integration of point-of-care testing and the use of digital health solutions are reshaping the landscape. There is a growing demand for rapid testing options that can provide results promptly in emergency settings, enhancing the ability to triage patients effectively. Manufacturers are also looking toward partnerships with technology companies to develop mobile applications and telehealth services that enable continuous monitoring of cardiac health, which can further improve patient management.
In recent times, trends such as personalized medicine and the move towards precision diagnostics have gained traction in the US market. Healthcare providers are increasingly interested in tailoring treatment plans based on individual patient profiles and biomarker levels. Additionally, regulatory bodies like the FDA are promoting streamlined approval processes for innovative cardiac biomarker tests, which further stimulates market growth.
With aging demographics and an emphasis on chronic disease management, the future of the US Cardiac Biomarkers Market looks promising as it continues to adapt to the evolving needs of healthcare providers and patients alike.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The prevalence of cardiovascular diseases in the United States has been steadily increasing, largely attributed to factors such as obesity, sedentary lifestyles, and aging populations. According to the American Heart Association, approximately 697,000 individuals die from heart disease annually in the US, representing nearly 1 in every 5 deaths. This growing prevalence of cardiovascular conditions is a major driver for the US Cardiac Biomarkers Market Industry as healthcare providers continuously seek innovative diagnostic tools to improve patient outcomes.
The introduction of advanced cardiac biomarkers aids in early detection and risk stratification, enhancing treatment effectiveness. Companies such as Abbott Laboratories and Roche have been at the forefront, focusing their Research and Development investments on the development of new biomarkers aimed at better diagnosis and management of heart diseases. The rising demand for such innovations is expected to significantly contribute to market growth in the coming years.
Advancements in diagnostic technologies have been a crucial factor in enhancing the accuracy and efficiency of cardiac biomarker tests. Innovations, including point-of-care testing platforms and high-sensitivity assays, have elevated the US Cardiac Biomarkers Market Industry significantly. The US Food and Drug Administration has recently approved several high-sensitivity troponin assays that allow for faster and more reliable heart attack diagnoses.
Research conducted by the National Institutes of Health indicates that the introduction of these technologies can reduce the time to diagnosis by up to 50%. Hence, the integration of advanced technologies not only improves patient management but also drives the demand for new biomarker tests and products from established companies like Abbott and Siemens Healthineers, who invest heavily in this domain.
The trend toward personalized or precision medicine is transforming the healthcare landscape in the United States, particularly in the field of cardiology. The incorporation of biomarker-driven strategies to tailor treatments to individual patient profiles enhances treatment efficacy and safety. The National Institutes of Health has noted that personalized medicine can lead to improvements in treatment outcomes and could potentially reduce healthcare costs by preventing ineffective treatments.
This growth in demand for personalized medicine practices is driving the US Cardiac Biomarkers Market Industry as institutions such as Mayo Clinic and Cleveland Clinic continue to advocate for the adoption of biomarker tests. With an increase in clinical trials aimed at personalizing cardiovascular therapies, the momentum for biomarker development is expected to intensify, creating further market opportunities.
In the United States, government initiatives aimed at combating cardiovascular diseases are spurring growth in the cardiac biomarkers sector. Through programs such as the National Heart, Lung, and Blood Institute (NHLBI), significant funding has been allocated for research dedicated to innovative biomarker development and the enhancement of cardiovascular disease prevention strategies. A report indicated that federal funding for cardiovascular research approaches nearly 500 million USD annually, reflecting the growing recognition of heart diseases as a public health concern.
Such financial backing encourages collaborations between universities, research institutions, and private firms in the US Cardiac Biomarkers Market Industry, driving innovation and development of new biomarker solutions. By promoting such partnerships, the government plays a critical role in shaping a robust pipeline for future growth in the market.
The US Cardiac Biomarkers Market is steadily evolving, with a strong focus on the Type segmentation, which includes key components such as Creatine Kinase (CK-MB), Troponins T, Myoglobin, BNPs, Ischemia-modified albumin (IMA), and others. In the context of cardiac events, biomarkers play an indispensable role in diagnostics and patient monitoring, particularly in acute coronary syndrome. Troponins T have emerged as a major player in the Type segment due to their high sensitivity and specificity in diagnosing myocardial infarction, making them a gold standard for clinicians across the United States.
Meanwhile, Creatine Kinase (CK-MB) continues to be utilized as a traditional marker, particularly for the early assessment of heart injury. The Biomarkers such as Myoglobin are gaining traction; they are known for their rapid release into the bloodstream following cardiac damage, enabling timely intervention. BNPs are crucial for evaluating heart failure, offering a vital diagnostic tool in emergency care settings. Meanwhile, Ischemia-modified albumin (IMA) has garnered interest for its potential to improve diagnosis in ischemic conditions.
Each of these components addresses specific clinical needs and directly contributes to increasing diagnostic precision in the US Cardiac Biomarkers Market. With the rising prevalence of cardiovascular diseases and increased healthcare expenditure in the US, there's an intensified focus on advanced diagnostics, which opens up substantial opportunities for innovation in cardiac biomarkers. The Types segment will likely experience continued growth driven by advancements in laboratory technology and rising consumer awareness regarding heart health.
This segment's diversity aids healthcare providers in making informed decisions, ultimately enhancing patient outcomes through personalized medicine approaches tailored to individual profiles, thereby significantly impacting overall health management strategies in cardiovascular care across the nation.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Location of Testing segment within the US Cardiac Biomarkers Market plays a crucial role in the effective diagnosis and management of cardiac diseases. As healthcare continues to evolve, both Point of Care and Laboratory Testing are becoming increasingly significant in delivering timely results. Point of Care testing is favored for its rapid turnaround time, enabling healthcare providers to make swift clinical decisions, especially in emergency settings. This location of testing meets the growing demand for immediate diagnostics, which is essential considering the rising incidence of cardiovascular diseases across the United States.
On the other hand, Laboratory Testing remains a cornerstone due to its comprehensive analytical capabilities and the ability to perform a wider array of tests, making it more suitable for complex cases that require detailed biomarkers analysis. Furthermore, advancements in technology and the increased adoption of telehealth services amplify the effectiveness of these testing locations. The trend toward decentralization in healthcare emphasizes the importance of both testing types as they contribute to improved patient outcomes and are likely to remain key drivers in the overall US Cardiac Biomarkers Market growth.
The US Cardiac Biomarkers Market has shown notable potential in the Application segment, serving critical roles in diagnosing and managing various cardiovascular diseases. Myocardial Infarction represents a significant area within this segment, as timely identification can drastically enhance patient outcomes. Similarly, Congestive Heart Failure is becoming increasingly prevalent, necessitating advanced biomarkers for effective monitoring and treatment strategies.
Acute Coronary Syndrome is another vital application, with biomarkers playing a crucial role in risk assessment and guiding therapeutic decisions. Atherosclerosis, characterized by arterial plaque buildup, relies on biomarkers for early detection and management, underscoring their importance in preventing severe cardiovascular events. The integration of advanced technologies in biomarker development is a growing trend, further driving market growth.
As healthcare demands shift towards personalized medicine, the significance of accurate diagnostics and targeted therapies only intensifies, indicating strong future opportunities within these applications in the US Cardiac Biomarkers Market. The market growth is fueled by an increasing incidence of heart diseases and a rising focus on preventive healthcare measures among both consumers and healthcare providers.
The US Cardiac Biomarkers Market is characterized by rapid growth and intense competition, emerging as a vital segment within the broader healthcare landscape. This market is primarily driven by the increasing prevalence of cardiovascular diseases, a growing aging population, and advancements in diagnostic technology. Key aspects that shape the competitive landscape include innovation in product development, collaboration with healthcare providers, and the establishment of extensive distribution networks. Companies compete on the ability to offer reliable, accurate, and timely diagnostic solutions that help in better patient management and care.
The market dynamics also involve regulatory considerations and the need for manufacturers to comply with stringent quality standards, which further influences competitive strategies.
Danaher Corporation holds a prominent position in the US Cardiac Biomarkers Market, leveraging its strong reputation for innovation and quality. The company focuses on developing and providing comprehensive diagnostic solutions that cater to the needs of healthcare providers and laboratories across the country. Its strengths are highlighted by a robust portfolio of advanced technologies in molecular and immunoassay diagnostics that facilitate the accurate measurement of cardiac biomarkers.
Danaher Corporation benefits from its strong distribution channels, which ensure accessibility to its products, as well as its commitment to research and development, allowing it to stay at the forefront of emerging trends in cardiac diagnostics. Their exceptional customer support and strategic partnerships with healthcare institutions further bolster their market presence in the US.
Quidel Corporation is another key player within the US Cardiac Biomarkers Market, offering a range of innovative products and services designed to enhance cardiac care. The company is recognized for its focus on rapid diagnostic testing solutions, which enable healthcare professionals to quickly identify cardiac conditions. Key offerings include point-of-care tests and laboratory diagnostics that streamlines the process of measuring biomarkers associated with cardiovascular disease.
Quidel Corporation has established a solid market presence in the US, benefiting from its strong research capabilities and well-established brand reputation. Strategic mergers and acquisitions have also played a significant role in expanding their product offerings and capabilities, further enhancing their competitive positioning. The company continues to invest in technological advancements and maintain robust relationships with healthcare partners to drive growth in the US market.
The US Cardiac Biomarkers Market is experiencing notable developments, particularly in the context of high demand for accurate and rapid diagnostic tools amid rising cardiovascular diseases. Companies such as Danaher Corporation and Abbott Laboratories are actively expanding their product portfolios, investing in new technologies to enhance diagnostic capabilities. In July 2023, Roche Diagnostics announced a strategic partnership with a prominent company to bolster their research initiatives in cardiac markers, reflecting a trend towards collaboration for improved diagnostic efficiency.
Additionally, Quidel Corporation saw significant growth in its market valuation, attributed to increasing sales of its innovative testing solutions. Moreover, in August 2023, Thermo Fisher Scientific completed its acquisition of a diagnostic asset that is anticipated to broaden its cardiac biomarker offerings, reinforcing its position in the market. Major industry players are continuously innovating, with HemoSonics launching a new point-of-care testing device in early 2023 aimed at providing rapid results for clinicians. These developments denote a thriving market environment, vital in addressing the escalating prevalence of heart-related ailments across the United States.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 2.77(USD Billion) |
| MARKET SIZE 2024 | 3.6(USD Billion) |
| MARKET SIZE 2035 | 12.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.981% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Danaher Corporation, Quidel Corporation, BioRad Laboratories, Roche Diagnostics, Grifols, Abbott Laboratories, PerkinElmer, Thermo Fisher Scientific, Cardinal Health, Siemens Healthineers, Ortho Clinical Diagnostics, HemoSonics, General Electric, Microsensors, Bayer AG |
| SEGMENTS COVERED | Type, Location of Testing, Application |
| KEY MARKET OPPORTUNITIES | Rapid technological advancements, Increased demand for early diagnosis, Growth in home testing solutions, Expansion of personalized medicine, Rising prevalence of cardiovascular diseases |
| KEY MARKET DYNAMICS | growing prevalence of cardiovascular diseases, increasing demand for rapid diagnostic tests, technological advancements in biomarker development, rising geriatric population, favorable reimbursement policies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Cardiac Biomarkers Market is expected to be valued at 3.6 USD Billion in 2024.
By 2035, the US Cardiac Biomarkers Market is projected to reach a value of 12.5 USD Billion.
The US Cardiac Biomarkers Market is expected to grow at a CAGR of 11.981% from 2025 to 2035.
In 2024, Troponins T is expected to have the largest market share in the US Cardiac Biomarkers Market, valued at 1.2 USD Billion.
The market value for Creatine Kinase (CK-MB) is projected to be 2.8 USD Billion by 2035.
Major players in the market include Danaher Corporation, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.
The market value of BNPs in the US Cardiac Biomarkers Market is expected to be 0.9 USD Billion in 2024.
Imyoglobin is expected to show significant growth, reaching a valued market size of 2.0 USD Billion by 2035.
Growth drivers include the increasing prevalence of cardiovascular diseases and advancements in biomarker technologies.
The competitive landscape has seen increasing involvement from leading companies, enhancing innovation and product offerings.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
